EUCTR2009-016914-25-DE进行中（未招募）不适用
CEDRIC: Clopidogrel- Effects on Diameter Reduction and Intimal Hyperplasia in Long-term Follow up after Cardiac Transplantation - CEDRIC trial
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Gender: men and women
- •In women: During the pharmacological treatment a recognized method of contraception must be used.
- •Written consent to participate in the clinical study, including consent to data protection regulations.
- •Heart transplantation >= 2,5 years before.
- •Taking of Everolimus as basic immunosuppression for at least 4 weeks and for a maximum of 6 months in addition.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •Known over-sensitivy to Clopidogrel or another constituent of the preparation.
- •Age < 18 years
- •Pregnant or breast feeding women
- •Heart transplantation < 2 years ago
- •Acute bleeding
研究者
相似试验
已完成
1 期
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy SubjectsHealthyNCT03430661Viatris Innovation GmbH77
已完成
2 期
The effect of clopidogrel in prevention of access graft thrombosis in upper extremity.Chronic Renal Failure -Hemodialysis.Chronic Renal Failure -DialysisIRCT2013012412256N1Kermanshah Univesity of Medical sciences50
进行中（未招募）
1 期
Pilot Study related to the effect of clopidogrel on plasmatic soluble CD40 ligand during systemic lupus erythematoussystemic lupus erythematousEUCTR2014-003733-25-FRCHU de BORDEAUX30
已完成
不适用
Interaction between human immunodeficiency virus (HIV) drugs (non-nucleoside reverse transcriptase inhibitors [NNRTIs]) and anti-platelet agentsISRCTN68035289Royal Liverpool University Hospital and the University of Liverpool?s Biomedical Research Centre (UK)37
进行中（未招募）
不适用
Kann der antiaggregatorische Effekt von Clopidogrel und Acetylsalicylsäure durch die Gabe von Thrombozytenkonzentraten aufgehoben werden? - PAC_2009Studie an gesunden Probanden. Zweck dieser Studie: Können autologe Thrombozyten-Konzentrate die Wirkung von Clopidogrel und Acetylsalicylsäure aufheben?EUCTR2009-018108-17-ATMedizinische Universität Graz